Telehealth companies offering compounded versions of popular drugs like Ozempic represent a novel marketplace, catering to customers unable to access conventional prescriptions.
Eli Lilly's introduction of low-dose Zepbound vials reflects a response to market demand, aiming to extend access for patients whose insurance fails to cover obesity medications.
The rise of compounded alternatives signifies millions of patients seeking cheaper solutions as insurers restrict access to weight-loss drugs to manage soaring costs.
Lilly's strategy to reduce its drug prices through direct sales underscores a competitive tension with telehealth companies, hinting at a fight for market share in a booming industry.
Collection
[
|
...
]